Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark W Lowdell

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Cytotherapy|January 11, 2025
Considerations for manufacturing of cell and gene medicines for clinical developmentMark W Lowdell
Frontiers in Immunology|December 11, 2013
Tumor-primed NK cells: waiting for the green lightMay Sabry, Mark W Lowdell
British Journal of Haematology|October 18, 2016
The expanding role of the clinical haematologist in the new world of advanced therapy medicinal productsMark W Lowdell, Amy Thomas
Frontiers in Immunology|July 27, 2023
Bringing function to the forefront of cell therapy: how do we demonstrate potency?Mark W Lowdell, Ben Weil
Stem Cells Translational Medicine|May 17, 2020
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancerMay Sabry, Mark W Lowdell
Cytotherapy|July 18, 2012
Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cellsAndrea Knight, Stephen Mackinnon, Mark W Lowdell
Lancet (London, England)|June 26, 2012
Use of compassionate-case ATMP in preclinical data for clinical trial applicationsMark W Lowdell, Martin Birchall, Adrian J Thrasher
Cells|February 25, 2023
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic SyndromeHelena Arellano-Ballestero, May Sabry, Mark W Lowdell
Cytotherapy|March 27, 2019
Characterization of human natural killer cells for therapeutic useArnika K Wagner, Evren Alici, Mark W Lowdell
Cytotherapy|January 19, 2019
T-cell receptor gene-modified cells: past promises, present methodologies and future challengesRita Tendeiro Rego, Emma C Morris, Mark W Lowdell
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Cytotherapy|January 11, 2025
Considerations for manufacturing of cell and gene medicines for clinical developmentMark W Lowdell
Frontiers in Immunology|December 11, 2013
Tumor-primed NK cells: waiting for the green lightMay Sabry, Mark W Lowdell
British Journal of Haematology|October 18, 2016
The expanding role of the clinical haematologist in the new world of advanced therapy medicinal productsMark W Lowdell, Amy Thomas
Frontiers in Immunology|July 27, 2023
Bringing function to the forefront of cell therapy: how do we demonstrate potency?Mark W Lowdell, Ben Weil
Stem Cells Translational Medicine|May 17, 2020
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancerMay Sabry, Mark W Lowdell
Cytotherapy|July 18, 2012
Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cellsAndrea Knight, Stephen Mackinnon, Mark W Lowdell
Lancet (London, England)|June 26, 2012
Use of compassionate-case ATMP in preclinical data for clinical trial applicationsMark W Lowdell, Martin Birchall, Adrian J Thrasher
Cells|February 25, 2023
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic SyndromeHelena Arellano-Ballestero, May Sabry, Mark W Lowdell
Cytotherapy|March 27, 2019
Characterization of human natural killer cells for therapeutic useArnika K Wagner, Evren Alici, Mark W Lowdell
Cytotherapy|January 19, 2019
T-cell receptor gene-modified cells: past promises, present methodologies and future challengesRita Tendeiro Rego, Emma C Morris, Mark W Lowdell
Pageof 8